Therapeutic Focus

Therapeutic Focus Top 25 infectious disease products in 2015

Top 25 infectious disease products in 2015

To no surprise, Gilead Sciences' Harvoni and Sovaldi were the top-selling infectious disease products in 2015.

Therapeutic Focus Drugmakers renew interest in antibiotic development

Drugmakers renew interest in antibiotic development

The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.

Therapeutic Focus Competition may threaten Gilead as market leader

Competition may threaten Gilead as market leader

Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.

Therapeutic Focus Top 20 autoimmune products, 2015

Top 20 autoimmune products, 2015

AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.

Therapeutic Focus With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

The bar for market success has been set high for baricitinib.

Therapeutic Focus Fueled by precision medicine, drugmakers delve deeper in autoimmune diseases

Fueled by precision medicine, drugmakers delve deeper in autoimmune diseases

Drugmakers are working toward developing drugs in lupus, celiac disease, and other conditions that have rarely captured their attention in the past.

Therapeutic Focus Advaxis, Farrah Fawcett Foundation collaborate to develop anal cancer drug

Advaxis, Farrah Fawcett Foundation collaborate to develop anal cancer drug

The biotech company is working with the foundation and Brown University to develop new regimens for the socially stigmatized condition.

Therapeutic Focus Top 25 orphan drugs, by 2015 global sales

Top 25 orphan drugs, by 2015 global sales

Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.

Therapeutic Focus Rare disease drugs facing questions over prices, incentives

Rare disease drugs facing questions over prices, incentives

With drugs treating rare diseases priced at sky-high levels, can the healthcare system shoulder the financial burden they impose?

Therapeutic Focus New cardiovascular drugs raise concerns about pricing, efficacy

New cardiovascular drugs raise concerns about pricing, efficacy

With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.

OPINION

Email Newsletters